长链非编码RNA高表达与小细胞肺癌预后不良相关性的Meta分析

目的 旨在确定长链非编码RNA表达水平在小细胞肺癌(SCLC)中的潜在预后和临床病理价值。方法 计算机全面检索PubMed、Embase、Cochrane Library、中国知网、万方数据库、维普中文期刊全文数据库和中国生物医学文献数据库等在线数据库,收集 LncRNA高表达与SCLC预后的相关性研究(建库至2020年5月)。由2名研究人员独立筛选文献、提取资料,质量评价后使用统计软件STATA12.0进行Meta定量综合分析。结果 共计纳入13个病例-对照研究,包括1 302例患者。结果表明:LncRNA高表达的SCLC患者更易早期广泛转移比值比(Odds ratio, OR)=6.10,95%置信区间(confidence interval,CI)(4.69,7.93),P<0.01]、对化疗药物反应较差OR=5.17, 95%CI(3.44, 7.77),P<0.01]、生存状态较差OR=5.96, 95%CI(4.22, 8.40),P<0.01]、总生存期(OS)风险比 (hazard ratio, HR)=3.33,95%CI(2.65,4.19),P<0.01]及无进展生存期(PFS)HR=4.88,95%CI(3.00,7.94),P<0.01]更短。结论 LncRNA高表达可以预测SCLC患者的不良生存率和不良的临床病理特征,可能是潜在的预后标志物。然而,这需要更多高质量研究的支持。

Relationship between long non-coding RNA overexpression and poor prognostic of small cell lung cancer: a meta-analysis

Objective This meta-analysis aims to come to a judgement the clinical value of long non-coding RNA(LncRNA) as a prognostic marker and potential clinicopathological value in small cell lung cancer(SCLC).Methods A comprehensive search of available literature resources included PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, CQVIP Journal Database, and Chinese Biology Medicine database to study the association between LncRNA overexpression and prognosis for SCLC up to May 2020. Related information was screened and extracted from the qualified studies by two independent reviewers. After the quality evaluation, the statistical software STATA12.0 was used to perform Meta quantitative comprehensive analysis. Results A total of thirteen case-control studies including 1302 SCLC patients were involved. The results revealed that: LncRNA overexpression patients had poor disease stage (Odds ratio, OR]=6.10, 95% confidence intervalCI] (4.69, 7.93), P<0.01), poorer chemosensitivity (OR=5.17, 95%CI3.44, 7.77], P<0.01), poorer survival status (OR=5.96, 95%CI4.22, 8.40], P<0.01), overall survival (OS) (hazard ratio, HR]=3.33, 95%CI2.65, 4.19], P<0.01) and progression-free survival (PFS) (HR=4.88, 95%CI3.00, 7.94), P<0.01).Conclusion LncRNA overexpression can predict poor survival and poor clinicopathological features in SCLC patients, may be a potential prognostic marker. However, the above conclusion still needs to be supported by more high-quality studies.